OQP Administers First Patient Dose of 'Oregovomab' in US for Global Phase 3 Clinical Trial

Dr. Sunil Gupta Appointed as Chief Medical Officer (CMO)
Clinical Trials Planned in China through Collaboration with Oncovent

[Asia Economy Reporter Jang Hyowon] OncoQuest Pharmaceuticals (hereinafter 'OQP', CEO Changhyun Lee) announced on the 13th that it has initiated the first drug administration of its immuno-oncology drug 'Oregovomab' in the global Phase 3 clinical trial to the first patient in the United States.

The global Phase 3 clinical trial of Oregovomab is being conducted in collaboration with the U.S. Gynecologic Oncology Group Foundation and the global clinical trial contract research organization leader IQVIA. The global Phase 3 trial is expected to enroll 602 patients across 140 clinical sites in 17 countries worldwide. Information about the clinical trial can be found in the U.S. clinical trial registry under NCT number 0449811.

To successfully complete this global Phase 3 trial, OQP appointed Dr. Sunil Gupta as Chief Medical Officer (CMO). Dr. Gupta worked for 22 years at Sanofi and Rhone-Poulenc Rorer, and most recently served as Vice President of Regulatory and Pharmacovigilance at Agenus Inc. for two years.

He has led multiple oncology clinical trial programs for approvals from the U.S. FDA, European EMA, and other global agencies, and possesses over 30 years of experience in clinical development, medical, and regulatory affairs focused on oncology drug development, demonstrating outstanding leadership.

Dr. R. Madiyalakan, Chairman of the OQP Board, stated, “We welcome Dr. Gupta to our clinical development team and are pleased to have initiated the first drug administration in the global Phase 3 trial.”

Meanwhile, OQP is also conducting clinical trials in China in cooperation with OncoVent, which holds the commercialization license for Oregovomab in the Chinese region.